Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques

Drug Metabolism and Disposition

Volumn 28, Issue 1, 2000, Pages 79-88

  Davi, H ^a,c   Tronquet, C ^a   Miscoria, G ^a   Perrier, L ^a   Dupont, P ^b   Caix, J ^b   Simiand, J ^b   Berger, Y ^a  

^a SANOFI   (France)

^b Preclin Drug Metab Pharmacokin   (France)

^c NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CARBON 14; DRUG METABOLITE; IRBESARTAN;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; MACACA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BILE; BIPHENYL COMPOUNDS; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; FEMALE; LIVER; MACACA FASCICULARIS; MACACA MULATTA; MALE; MICE; MICE, INBRED STRAINS; PREGNANCY; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TISSUE DISTRIBUTION;

MACACA; ORYCTOLAGUS CUNICULUS;

EID: 0033975483     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Boudinot FD and Jusko WJ (1984) Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 73:774-780.
2. Bourrié M, Meunier V, Berger Y and Fabre G (1999) Role of cytochrome P4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 27:288-296.
3. Candesartan celexitel (Atacand) product information (1998) Astra-Merck, West Point, PA.
4. 1 angiotensin II receptor antagonist. J Pharmacol Exp Ther 265:826-834.
5. Chando TJ, Everett DW, Kahle AD, Starret AM, Vachharajani N, Shyu WC, Kripalani KJ and Barbhaiya RH (1998) Biotransformation of irbesartan in man. Drug Metab Dispos 26:408-417.
6. Christ DD, Wong PC, Nancy Wong Y, Hart SD, Quon CY and Lam GN (1994) The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. J Pharmacol Exp Ther 268:1199-1203.
7. Cox Gad S and Chengelis CP (1992) in Animal Models in Toxicology, pp 111-113, Marcel Dekker, New York.
8. DeGraaf GL, Pals DT, Cough SJ and Lawson JA (1993) Hormonal and cardiovascular effects of losartan (DuP753), an angiotensin receptor antagonist, in nonhuman primates. J Pharmacol Exp Ther 264:6-10.
9. Fachinformation (1996) Diovan, valsartan. Ciba-Geigy GmbH, Wehr, Germany.
10. Gillis JC and Markham A (1997) Irbesartan: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 54:885-902.
11. 1 receptor antagonist in hypertensive rat models. Eur J Pharmacol 264:307-316.
12. 1-receptor antagonist, in conscious monkeys. J Hypertens 11:1187-1194.
13. Losartan (Cozaar) product information (1998) Merck and Co, Inc, West Point, PA.
14. Marino MR, Langenbacher K, Ford NV and Uderman HD (1998) Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 38:246-255.
15. Michel JB, Wood J, Hofbauer KG, Corvol P and Menard J (1984) Blood pressure effects of renin inhibition by human renin antiserum in normotensive marmosets. Am J Physiol 246:F309-F316.
16. Miwa K, Murakami H, Masaki K, Iwasaki M and Yoshimura M (1998) In vitro hepatic metabolism of candesartan to its inactive metabolite, CV-15959. J Hypertens 16 (Suppl 2):S128.
17. Mulder G (1986) Sex related differences in drug conjugation and their consequences for drug toxicity; sulfation, glucuronidation and glutathione conjugation. Chem-Biol Interact 57:1-15.
18. Necciari J, Denolle T, Le Croz F, Donazollo Y, Pastor G and Sissmann J (1994) Pharmacokinetics of SR47436 (BMS186295), a new angiotensin II receptor antagonist in man. J Hypertens 12 (Suppl 3):88.
19. Nishikawa K, Naka T, Chatani F and Yoshimura Y (1997) Candesartan cilexetil: A review of its preclinical pharmacology. J Hum Hypertens 11 (Suppl 2):S9-S17.
20. Omura T and Sato R (1964) The carbon monoxide binding pigment of liver microsomes. J Biol Chem 239:2370-2378.
21. Pollard HB, Menard R, Brandt HA, Pazoles CJ, Creutz CE and Ramu A (1978) Application of Bradford's protein assay to adrenal gland subcellular fractions. Anal Biochem 86:761-763.
22. 1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys. Br J Pharmacol 111:145-150.
23. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
24. Spielberg S, McCrea J, Cribb A, Rushmore T, Waldman S, Bjornsson T, Lo MW and Goldberg M (1996) A mutation in CYP2C9 is responsible for decrease metabolism of losartan. Clin Pharmacol Ther 59:215.
25. Ullberg S (1954) Studies on the distribution and fate of 35S-labelled benzylpenicillin in the body. Acta Radiologica 118 (Suppl 118):1-110.
26. Vachharajani N, Shyu WC, Smith R, Chang SY, Greene D and Barbhaiya R (1995) The effects of age and gender on the pharmacokinetics of irbesartan. Pharm Res 12:S-388.
27. Valsartan (Diovan) product information (1998) Ciba-Geigy, Summit, NJ.
28. Waldmeier F, Flesch G, Müller P, Winkler T, Kriemler HP, Bühlmayer P and De Gasparo M (1997) Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 27:59-71.
29. Williamson KM, Patterson JH, Pieper JA, McQueen RH and Adams KF Jr (1997) Effects of erythromycin or rifampin on steady state losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 61:202.
30. Wong PC, Christ DD, Wong YN and Lam GN (1996) Nonpeptide angiotensin II receptor antagonist: Pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan. Pharmacology 52:25-29.
31. Wood JM, Gulati N, Forgiarini P, Fuhrer W and Hofbauer KG (1985) Effects of a specific and long-acting renin inhibitor in the marmoset. Hypertension 7:797-803.